Screener
Exelixis EXEL Gross product revenues — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Exelixis’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q3 2026
- Accession
- 0000939767-26-000098
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Product revenues: | ||||
| Gross product revenues | $812,782 | $745,280 | $1,608,136 | $1,466,991 |
| Discounts and allowances | (239,757) | (225,266) | (480,134) | (433,694) |
| Net product revenues | 573,025 | 520,014 | 1,128,002 | 1,033,297 |
| Collaboration revenues: | ||||
| License revenues | 59,810 | 49,301 | 116,758 | 91,781 |
| Collaboration services revenues | (4,145) | (1,054) | (5,258) | (1,370) |
| Collaboration revenues | 55,665 | 48,247 | 111,500 | 90,411 |
Item 1. Financial Statements.
FAQ
- What is Exelixis's gross product revenues — total revenues?
- Exelixis (EXEL) reported gross product revenues — total revenues of $812.78M in Q2 2026.
- How has Exelixis's gross product revenues — total revenues changed year-over-year?
- Exelixis's gross product revenues — total revenues increased by 9.1% year-over-year, from $745.28M to $812.78M.
- What is the long-term trend for Exelixis's gross product revenues — total revenues?
- Over 4 years (2021 to 2025), Exelixis's gross product revenues — total revenues has grown at a 20.0% compound annual growth rate (CAGR), from $1.45B to $3.01B.
- What does gross product revenues — total revenues mean?
- This metric represents the total gross revenue generated from the sale of pharmaceutical products before accounting for deductions such as rebates, discounts, and returns. It serves as a primary indicator of the market demand and commercial adoption of the company's therapeutic portfolio. By tracking gross product sales, investors can assess the top-line performance of the company's core oncology assets independently of net pricing adjustments.
Ask your AI about Exelixis's gross product revenues — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude